Novartis AG Company Profile (NYSE:NVS)

About Novartis AG

Novartis AG logoNovartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company's segments include Pharmaceuticals, Alcon and Sandoz. Its Pharmaceuticals segment is engaged in researching, developing, manufacturing, distributing and selling patented prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines. Its Alcon segment is engaged in developing, manufacturing and selling eye care products across the world. Its Sandoz segment is engaged in developing, manufacturing and marketing generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars and drug substances that are not protected by valid and enforceable third-party patents.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: NVS
  • CUSIP:
Key Metrics:
  • Previous Close: $80.30
  • 50 Day Moving Average: $82.31
  • 200 Day Moving Average: $77.40
  • Trailing P/E Ratio: 28.67
  • Foreward P/E Ratio: 15.84
  • P/E Growth: 2.79
  • Market Cap: $191.21B
  • Outstanding Shares: 2,381,221,000
  • Beta: 0.58
Additional Links:
Companies Related to Novartis AG:

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.07)
Consensus Price Target: $93.00 (15.82% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
DateFirmActionRatingPrice TargetDetails
7/19/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
7/12/2016Bank of America Corp.Reiterated RatingHoldView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralView Rating Details
5/13/2016Jefferies GroupReiterated RatingBuyView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details
4/22/2016Barclays PLCUpgradeUnderweight -> Equal WeightView Rating Details
4/14/2016Credit Suisse Group AGReiterated RatingHoldView Rating Details
4/12/2016Morgan StanleyDowngradeEqual Weight -> UnderweightView Rating Details
4/5/2016ArgusInitiated CoverageHold -> HoldView Rating Details
1/28/2016BNP ParibasDowngradeOutperform -> NeutralView Rating Details
1/7/2016Goldman Sachs Group Inc.Boost Price TargetNeutral$89.00 -> $92.00View Rating Details
11/23/2015VontobelDowngradeHoldView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00View Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformView Rating Details
7/7/2015Oddo SecuritiesInitiated CoverageBuyView Rating Details
6/25/2015HSBCInitiated CoverageBuyView Rating Details
6/22/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
3/4/2015NatixisUpgradeNeutral -> BuyView Rating Details
1/5/2015Cowen and CompanyUpgradeMarket Perform -> Outperform$95.00 -> $105.00View Rating Details
11/13/2014Kepler Capital MarketsUpgradeHold -> BuyView Rating Details
(Data available from 8/24/2014 forward)


Earnings History for Novartis AG (NYSE:NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.10$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.21$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3$1.31$1.33$14.51 billion$14.70 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014$1.27$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novartis AG (NYSE:NVS)
Current Year EPS Consensus Estimate: $4.73 EPS
Next Year EPS Consensus Estimate: $5.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$1.17$1.18$1.17
Q2 20163$1.12$1.21$1.17
Q3 20161$1.19$1.19$1.19
Q4 20162$1.13$1.24$1.19
(Data provided by Zacks Investment Research)


Current Dividend Information for Novartis AG (NYSE:NVS)
Annual Dividend:$2.30
Dividend Yield:2.86%
Payout Ratio:82.14% (Based on Trailing 12 Months of Earnings)
48.63% (Based on Current Year Consensus EPS Estimate)
45.36% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:2.40% (3 Year Average)

Dividend History for Novartis AG (NYSE:NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Novartis AG (NYSE:NVS)
DateHeadline logoWaiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares (NYSE:NVS) - August 24 at 6:19 PM logoNovartis AG (NYSE:NVS) Licenses LGT209 To Cyon Therapeutics, Inc., Teams Up With KRCS (NYSE:NVS) - August 24 at 6:19 PM logoNovartis AG (NYSE:NVS) Licenses LGT209 To Cyon Therapeutics, Inc., Teams Up With KRCS - Market Exclusive (NYSE:NVS) - August 24 at 9:39 AM logoNovartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics (NYSE:NVS) - August 24 at 9:39 AM logoCyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe Infection and Sepsis (NYSE:NVS) - August 23 at 6:44 PM logoNovartis (NVS), Cyon Therapeutics Enter Licensing Agreement for LGT-209 (NYSE:NVS) - August 23 at 6:44 PM
News IconZymeworks signs licence deal with Burnaby biotech (NYSE:NVS) - August 23 at 11:01 AM logoNovartis AG (NYSE:NVS) Boasts Rating Of 2.26 - Stocks Daily (NYSE:NVS) - August 20 at 6:13 PM logoNovartis: First-Class Pharmaceuticals (NYSE:NVS) - August 19 at 6:29 PM logo5 Stocks That Beat The Market In A Crash (NYSE:NVS) - August 18 at 6:43 PM logoNovartis AG (NYSE:NVS) To Spend $100 Million On Expansion Of French mAb Plant - Market Exclusive (NYSE:NVS) - August 18 at 9:38 AM logoOzanimod May Prove to Be a Strong Growth Driver for Celgene (NYSE:NVS) - August 18 at 9:38 AM logoGenzyme Continued to Boost Growth for Sanofi in 2Q16 (NYSE:NVS) - August 18 at 9:38 AM logoWill Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges? - TCC (NYSE:NVS) - August 17 at 6:49 PM logoTurkey's investigation into drugmaker Novartis 'ongoing' -official (NYSE:NVS) - August 17 at 6:49 PM logoWill Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges? (NYSE:NVS) - August 16 at 6:42 PM logoNovartis AG (NYSE:NVS) To Spend $100 Million On Expansion Of French mAb Plant (NYSE:NVS) - August 16 at 9:50 AM logoValeant: Are the Salix and Dermatology Portfolios Recovering? (NYSE:NVS) - August 16 at 9:50 AM logoAllergan to Buy ForSight VISION5, Boost Glaucoma Pipeline (NYSE:NVS) - August 15 at 8:46 AM logoNovartis Korea executives charged with bribing doctors (NYSE:NVS) - August 13 at 9:28 AM logoNovartis AG (NYSE:NVS) Executives In South Korea Indicted For Illegal Rebate (NYSE:NVS) - August 12 at 6:41 PM logoWho Is Driving Novarti's Management Team? (NVS, BAYRY) (NYSE:NVS) - August 12 at 6:41 PM logoNovartis says bribe allegations in Turkey groundless, matter closed (NYSE:NVS) - August 12 at 9:46 AM logoNovartis AG (NYSE:NVS) Executives In South Korea Indicted For Illegal Rebate - Market Exclusive (NYSE:NVS) - August 11 at 7:01 PM logoNovartis could face S.Korea sales ban amid corruption allegations: media (NYSE:NVS) - August 11 at 7:01 PM logoLilly Breast Cancer Drug Study Rolls On, Pushing Back Launch Date (NYSE:NVS) - August 10 at 9:40 AM logoETF’s with exposure to Novartis AG : August 9, 2016 (NYSE:NVS) - August 9 at 6:49 PM logoHow Will Novartis (NVS) Stock React to Asthma Pill Trial Success? (NYSE:NVS) - August 8 at 6:47 PM logoCanada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients (NYSE:NVS) - August 8 at 6:47 PM logoWill Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020? (NYSE:NVS) - August 8 at 11:15 AM
News IconEarnings Review: Eli Lilly and Company (NYSE:LLY), Novartis AG (NYSE:NVS) - News Oracle (NYSE:NVS) - August 5 at 9:38 AM logoNovartis breast cancer pill gets breakthrough designation - Seeking Alpha (NYSE:NVS) - August 3 at 6:56 PM logoNovartis AG (NYSE:NVS)'s Partner Bioline RX Announce In-Licensing Of Liver Fibrosis Project - Market Exclusive (NYSE:NVS) - August 3 at 6:56 PM logoCan Novartis Win the Entresto Bet? (NYSE:NVS) - August 3 at 6:56 PM logoGenerics Keeping The Pressure On Big Pharma (NYSE:NVS) - August 3 at 6:56 PM
News IconHC Stocks Highlights: CIGNA Corporation (NYSE:CI), Novartis AG (ADR) (NYSE:NVS) - share market updates (press release) (NYSE:NVS) - August 3 at 9:50 AM logoGlaxoSmithKline’s Consumer Healthcare Grows in 2Q16 (NYSE:NVS) - August 3 at 9:50 AM logoCVS Cuts Coverage of Dozens of Drugs in Exclusion Expansion (NYSE:NVS) - August 2 at 6:53 PM
News IconStock Performance to Track: Novartis AG (NYSE:NVS) - News Oracle (NYSE:NVS) - August 2 at 11:29 AM logo3:15 am Novartis unit Alcon receives FDA approval for CyPass Micro-Stent for sale in the US (NYSE:NVS) - August 2 at 11:29 AM logoThese Drugs Were Key Growth Drivers for Amgen’s Revenue in 2Q16 (NYSE:NVS) - August 1 at 9:09 AM logoETF’s with exposure to Novartis AG : July 29, 2016 (NYSE:NVS) - July 29 at 1:44 PM logoTwo Buzzers within Analysts Radar: Medtronic plc (NYSE:MDT) , Novartis AG (NYSE:NVS) - Street Updates (NYSE:NVS) - July 28 at 9:45 AM
News IconStock under consideration: Novartis AG (NYSE:NVS) - News Oracle (NYSE:NVS) - July 28 at 9:45 AM logoAstraZeneca a bid target again? CEO says someone may spot value (NYSE:NVS) - July 28 at 8:36 AM logoAfter $1 billion buyout, team quickly builds another cancer-fighting company (NYSE:NVS) - July 27 at 6:54 PM logoAnalyst Recommendations for Roche: Buy, Hold, or Sell? (NYSE:NVS) - July 27 at 11:04 AM logoNovartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016 (NYSE:NVS) - July 26 at 10:15 AM
News IconA Look at the Stock Strength for Novartis AG (NYSE:NVS) - Engelwood Daily (NYSE:NVS) - July 22 at 6:25 PM
News IconAre Analysts Still Saying "Buy" this Stock: Novartis AG (NYSE:NVS) - TGP (NYSE:NVS) - July 22 at 6:25 PM


Novartis AG (NYSE:NVS) Chart for Wednesday, August, 24, 2016

Last Updated on 8/24/2016 by Staff